7-117480125-G-A
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 4P and 2B. PM1PM2BP4_Moderate
The NM_000492.4(CFTR):c.31G>A(p.Val11Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000184 in 1,613,864 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000492.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.31G>A | p.Val11Ile | missense_variant | 1/27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.31G>A | p.Val11Ile | missense_variant | 1/27 | 1 | NM_000492.4 | ENSP00000003084 | P2 |
Frequencies
GnomAD3 genomes AF: 0.000184 AC: 28AN: 152072Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000155 AC: 39AN: 250988Hom.: 0 AF XY: 0.000118 AC XY: 16AN XY: 135676
GnomAD4 exome AF: 0.000184 AC: 269AN: 1461674Hom.: 0 Cov.: 31 AF XY: 0.000182 AC XY: 132AN XY: 727146
GnomAD4 genome AF: 0.000184 AC: 28AN: 152190Hom.: 0 Cov.: 32 AF XY: 0.000148 AC XY: 11AN XY: 74398
ClinVar
Submissions by phenotype
Cystic fibrosis Uncertain:4
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Sep 05, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 17, 2023 | The p.V11I variant (also known as c.31G>A), located in coding exon 1 of the CFTR gene, results from a G to A substitution at nucleotide position 31. The valine at codon 11 is replaced by isoleucine, an amino acid with highly similar properties. This variant was detected in an individual with asthma in conjunction with a second CFTR alteration; however, the phase was not provided (Tzetis M et al. Hum. Genet., 2001 Mar;108:216-21). This variant was also identified in an individual with chronic pancreatitis (Palermo JJ et al. Pancreas, 2016 Oct;45:1347-52). In an asymptomatic individual, this variant was detected in conjunction with p.F508del; however, it is unclear if the phase was determined (Claustres M et al. Hum. Mutat., 2017 10;38:1297-1315). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on available evidence to date, the clinical significance of this alteration remains unclear. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 11 of the CFTR protein (p.Val11Ile). This variant is present in population databases (rs1800072, gnomAD 0.03%). This missense change has been observed in individual(s) with chronic pancreatitis and clinical manifestations consistent with the spectrum of cystic fibrosis (PMID: 15858154, 27171515). ClinVar contains an entry for this variant (Variation ID: 495928). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CFTR protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Nov 20, 2017 | - - |
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Nov 03, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Nov 17, 2020 | In the published literature, this variant has been reported in individuals with CF (PMID: 15858154 (2005)), CFTR-related disorders (PMIDs: 28801929 (2017), 27171515 (2016)), primary sclerosing cholangitis (PMID: 29807875 (2018)), and asthma (PMIDs: 22664493 (2012), 22324837 (2012), 11354633 (2001)). In addition, this variant has been observed in an asymptomatic individual who also carried the CFTR p.Phe508del pathogenic variant (PMID: 28603918 (2017)). The frequency of this variant in the general population, 0.00031 (40/128740 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is deleterious or benign. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Sep 07, 2023 | In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 34426522, 11354633, 27171515, 34996830, 15858154) - |
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Dec 27, 2018 | The CFTR c.31G>A; p.Val11Ile variant (rs1800072), is reported in the literature in individuals affected with chronic pancreatitis or asthma (Maurya 2012, Palermo 2016, Tzetis 2001). This variant is reported as uncertain significance by multiple laboratories in ClinVar (Variation ID: 495928), and is found in the non-Finnish European population with an allele frequency of 0.031% (40/128,740 alleles) in the Genome Aggregation Database. The valine at codon 11 is weakly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. Due to limited information, the clinical significance of the p.Val11Ile variant is uncertain at this time. References: Maurya N et al. Association of CFTR gene mutation with bronchial asthma. Indian J Med Res. 2012 Apr;135(4):469-78. Palermo JJ et al. Genophenotypic Analysis of Pediatric Patients With Acute Recurrent and Chronic Pancreatitis. Pancreas. 2016 Oct;45(9):1347-52. Tzetis M et al. CFTR gene mutations--including three novel nucleotide substitutions--and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet. 2001 108(3):216-21. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 28, 2023 | Variant summary: CFTR c.31G>A (p.Val11Ile) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00016 in 250988 control chromosomes (gnomAD). This frequency is not higher than the maximum estimated for a pathogenic variant in CFTR causing Cystic Fibrosis (0.013), allowing no conclusion about variant significance. The variant, c.31G>A, has been reported in the literature in individuals with various phenotypes including asthma, chronic pancreatitis, idiopathic azoospermia / oligozoospermia, and primary sclerosing cholangitis, all without strong evidence for causality (example, Tzetis_2001, Palermo_2016, Oud_2017, Werlin_2018). In addition, the variant was also reported in an asymptomatic individual along with p.Phe508del (Claustres_2017), in an individual reporting unspecified spectrum of CF (Schrijver_2005) and was found in trans with p.Phe508del during newborn screening (Skov_2019). These reports do not provide unequivocal conclusions about association of the variant with Cystic Fibrosis. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 22324837, 28603918, 22664493, 28801929, 27171515, 25735457, 16049310, 31682332, 11354633, 29807875). Multiple clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014, and all of them classified the variant as uncertain significance. Some submitters cite overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Hereditary pancreatitis Uncertain:1
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Jan 07, 2022 | - - |
Cystic fibrosis;C0238339:Hereditary pancreatitis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation;C2749757:Bronchiectasis with or without elevated sweat chloride 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 03, 2022 | - - |
CFTR-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 31, 2024 | The CFTR c.31G>A variant is predicted to result in the amino acid substitution p.Val11Ile. This variant has been reported in individuals with asthma, chronic pancreatitis, cystic fibrosis, primary sclerosing cholangitis, and male infertility (Tzetis et al. 2001. PubMed ID: 11354633; Palermo et al. 2016. PubMed ID: 27171515; Schrijver et al. 2005. PubMed ID: 15858154; Werlin et al. 2018. PubMed ID: 29807875; Table S4, Oud et al. 2017. PubMed ID: 28801929); however, additional details supporting pathogenicity were not provided. The individual with asthma who carried this variant also carried CFTR c.2T>C, which disrupts the start codon (Tzetis et al. 2001. PubMed ID: 11354633). This variant has also been detected in individuals who carry the common pathogenic variant c.1521_1523del (p.Phe508del) and are asymptomatic or considered healthy carriers (Claustres et al. 2017. PubMed ID: 28603918; Supporting Information Data, Skov et al. 2019. PubMed ID: 31682332). This variant is reported in 0.031% of alleles in individuals of European (non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Bronchiectasis with or without elevated sweat chloride 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | May 02, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at